Comprehensive Guide to Hepatitis Advances

?Section 1:?HEPATITIS: ADVANCES IN CLINICAL EVALUATION
1. Noninvasive assessment of liver disease severity: image-related
2. Noninvasive assessments of liver disease severity based on biomarkers
3. Conventional liver imaging in hepatitis
4. Nutrition in liver disease

Section II: VIRAL HEPATITIS
5. Antivirals against hepatitis viruses: basic mechanisms
6. Hepatitis A and hepatitis E
7. Hepatitis B: epidemiology, natural history, and diagnosis
8. Hepatitis B: treatment
9. Hepatitis C: epidemiology, natural history, and diagnosis
10. Hepatitis C: treatment
11. Hepatitis D

Section III: HEPATITIS: METABOLIC, ALCOHOL, AND DRUG INDUCED
12. Metabolic-associated fatty liver disease: epidemiology, natural history and diagnosis, current paradigm and definitions for MAFLD
13. Metabolic-associated fatty liver disease: pharmacological management
14. Non-pharmacological treatment approach in patients with metabolic dysfunctionassociated liver disease
15. Alcoholic hepatitis
16. Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method
17. Introduction to drug-induced liver injury

Section IV: HEPATITIS: CHOLESTATIC, GENETIC, AND AUTOIMMUNE CAUSES
18. Current paradigm and treatment options for autoimmune hepatitis
19. Hereditary hemochromatosis
20. Wilson disease
21. Alpha-1 antitrypsin deficiency

Section V: HEPATITIS: INFECTIONS AND SYSTEMIC CAUSES
22. Hepatitis: infections and systemic causes
23. HIV: hepatic manifestations of HIV and antiretroviral therapy
24. Systemic non-infectious hepatitis
25. Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection

Section VI: CHILDHOOD AND PREGNANCY
26. Hepatitis during childhood
27. Hepatitis during pregnancy

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Imunologia
• Ciências da vida: temas gerais

Alcoholic hepatitis; Alpha-fetoprotein (AFP); ALT; Antiviral drugs; Bulevirtide; Chronic hepatitis B; Cirrhosis; Cirrhosis and portal hypertension; Clinical characteristics; Corticosteroids; Covalently closed circular DNA (cccDNA); CpAMs; DAA therapy; Diagnosis; Diet; Diffuse liver diseases; Direct-acting antivirals; Early liver transplantation; Enhanced liver fibrosis (ELF) test; Enteral nutrition; Enterically transmitted hepatitis; Epidemiology; Exercise; Extrahepatic manifestation; Fibroscan; Fibrosis; Fibrosis-4 (FIB-4) index; Functional cure; Gene polymorphisms; Gene silencing; Global elimination; HBeAg; HBV; HBV DNA; HBV RNA; HCC; Hepatic encephalopathy; Hepatitis; Hepatitis A; Hepatitis B core-related antigen (HBcrAg); Hepatitis B surface antigen (HBsAg); Hepatitis B virus; Hepatitis C; Hepatitis D; Hepatitis delta antigen; Hepatitis E